Contrasting Inhibitor Therapeutics (OTCMKTS:INTI) and Syndax Pharmaceuticals (NASDAQ:SNDX)

Syndax Pharmaceuticals (NASDAQ:SNDX) and Inhibitor Therapeutics (OTCMKTS:INTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Syndax Pharmaceuticals and Inhibitor Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	N/A	N/A	-$209.36 million	($3.63)	-4.13
Inhibitor Therapeutics	N/A	N/A	-$3.03 million	($0.01)	-6.46

Inhibitor Therapeutics is trading at a lower price-to-earnings ratio than Syndax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Syndax Pharmaceuticals and Inhibitor Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	0	1	9	0	2.90
Inhibitor Therapeutics	0	0	0	0	0.00

Syndax Pharmaceuticals currently has a consensus price target of $36.20, indicating a potential upside of 141.17%. Given Syndax Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Inhibitor Therapeutics.

Risk and Volatility

Syndax Pharmaceuticals has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, Inhibitor Therapeutics has a beta of -0.56, indicating that its stock price is 156% less volatile than the S&P 500.

Profitability

This table compares Syndax Pharmaceuticals and Inhibitor Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%
Inhibitor Therapeutics	N/A	-70.65%	-40.64%

Summary

Syndax Pharmaceuticals beats Inhibitor Therapeutics on 6 of the 9 factors compared between the two stocks.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.